Rosuvastatin Slows Progression of Carotid Intima-Media Thickness: The METEOR-China Randomized Controlled Study

医学 瑞舒伐他汀 内膜中层厚度 内科学 颈总动脉 心脏病学 安慰剂 随机对照试验 临床终点 代理终结点 颈动脉疾病 颈动脉 病理 颈动脉内膜切除术 替代医学
作者
Huaguang Zheng,Hongwei Li,Yilong Wang,Zhanquan Li,Bo Hu,Xiaogang Li,Lu Fu,Hongtao Hu,Zhiyu Nie,Bilian Zhao,Di Wei,Björn Wilgot Karlson,Michiel L. Bots,XiangWen Meng,Yundai Chen,Yongjun Wang,Shiping Cao,Yefeng Cai,Daoquan Peng,Yaogao Fu
出处
期刊:Stroke [Lippincott Williams & Wilkins]
卷期号:53 (10): 3004-3013 被引量:45
标识
DOI:10.1161/strokeaha.120.031877
摘要

Background: Atherosclerosis is the leading cause of cardiovascular disease worldwide, including in China. Primary prevention, through lipid-lowering, could avert development of atherosclerosis. Carotid intima-media thickness (CIMT) is a well-validated measure of atherosclerosis used in intervention studies as the primary outcome and alternative end point for cardiovascular disease events. Methods: This randomized, double-blind, placebo-controlled, multicenter, parallel-group study assessed the effects of rosuvastatin 20 mg/d compared with placebo on progression of CIMT over 104 weeks in Chinese people with subclinical atherosclerosis. The primary end point was the annualized rate of change in mean of the maximum CIMT measurements taken 7× over the study period from each of 12 carotid artery sites (near and far walls of the right and left common carotid artery, carotid bulb, and internal carotid artery). Secondary end points included CIMT changes at different artery sites and lipid-parameter changes. Safety was also assessed. Results: Participants were randomized (1:1) to receive rosuvastatin (n=272) or placebo (n=271). Baseline characteristics were well balanced between groups. The change in mean of the maximum CIMT of the 12 carotid sites was 0.0038 mm/y (95% CI, −0.0023–0.0100) for the rosuvastatin group versus 0.0142 mm/y (95% CI, 0.0080–0.0204) for the placebo group, with a difference of −0.0103 mm/y (95% CI, −0.0191 to −0.0016; P =0.020). For the CIMT secondary end points, the results were generally consistent with the primary end point. There were clinically relevant improvements in lipid parameters with rosuvastatin. We observed an adverse-event profile consistent with the known safety profile of rosuvastatin. Conclusions: Rosuvastatin 20 mg/d significantly reduced the progression of CIMT over 2 years in Chinese adults with subclinical atherosclerosis and was well tolerated. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02546323.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小安完成签到,获得积分10
刚刚
永溺深海的猫完成签到,获得积分10
刚刚
敏感笑槐完成签到 ,获得积分10
刚刚
完美世界的应助被Jim采纳,获得10
刚刚
玖雾完成签到,获得积分10
1秒前
ltt发布了新的文献求助20
1秒前
你说什么我听不见完成签到,获得积分10
1秒前
1秒前
1秒前
初(*^▽^*)心的应助被NiaoJiang采纳,获得10
1秒前
Star1983完成签到,获得积分10
1秒前
1秒前
槐夏十三完成签到 ,获得积分10
2秒前
jiangxiaoxu完成签到,获得积分10
2秒前
chilin完成签到,获得积分10
2秒前
郭濹涵完成签到,获得积分10
3秒前
Saoirse完成签到 ,获得积分10
4秒前
传统的寒凝完成签到,获得积分10
4秒前
WX完成签到,获得积分10
5秒前
gaoxiansheng完成签到,获得积分10
5秒前
5秒前
guoke完成签到,获得积分10
6秒前
123发布了新的文献求助10
6秒前
dhn123完成签到,获得积分10
7秒前
ve完成签到 ,获得积分10
7秒前
Yan完成签到,获得积分10
8秒前
笑影完成签到,获得积分10
8秒前
儒雅松鼠完成签到,获得积分10
9秒前
Sue完成签到 ,获得积分10
10秒前
10秒前
彩色的大米完成签到,获得积分10
10秒前
75986686完成签到,获得积分10
10秒前
123456qi完成签到,获得积分10
11秒前
科研dog完成签到,获得积分10
11秒前
马米粒完成签到,获得积分10
11秒前
科研通AI6.4的应助被梁潇鸿采纳,获得10
12秒前
动听的平露完成签到,获得积分10
12秒前
12秒前
li完成签到,获得积分10
12秒前
伶俐的谷丝完成签到 ,获得积分10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180135
求助须知:如何正确求助?哪些是违规求助? 9570290
关于积分的说明 21809391
捐赠科研通 7776237
什么是DOI,文献DOI怎么找? 3433266
关于科研通互助平台的介绍 2557465
邀请新用户注册赠送积分活动 2479039